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Urinary tract infections (UTIs) are a frequent cause of morbidity in children and adults and aﬀect up to 10% of children; its
recurrence rate is estimated at 30–40%. UTI may occur in up to 50% of all women in their lifetimes and frequently require
medication. Recent advances have suggested that a deregulation of candidate genes in humansmay predispose patients to recurrent
UTI. The identification of a genetic component of UTI recurrences will make it possible to diagnose at-risk adults and to predict
genetic recurrences in their oﬀspring. Six out of 14 genes investigated in humans may be associated with susceptibility to recurrent
UTI in humans. In particular, the HSPA1B, CXCR1 & 2, TLR2, TLR4, TGF-β1 genes seem to be associated with an alteration of
the host response to UTIs at various levels.
1. Background
Urinary tract infections (UTIs) are a frequent cause of
morbidity in children and adults. UTIs aﬀect up to 10% of
the pediatric population [1] and the recurrence rate of UTI
in children is estimated at 30% to 40%, with the majority of
recurrences occurring in the first 12 months after the initial
infection [2, 3]. Recurrent UTI is more frequent in very
young females older than 6 months [4]. UTIs may occur in
up to 50% of all women in their lifetimes and 10%–15% of
cases require medication [5]. Susceptibility to recurrent UTIs
in women could be the result of a combination of various
risk factors such as periurethral bacterial colonization and
Escherichia coli virulence [6].
The pathogenesis of recurrent UTIs consists of the three
classic components of any infection: host, pathogen and
environment [6]. The severity of a UTIs is determined by the
innate defense mechanisms of the host and by the virulence
of the infecting agents. The pathogenesis of the inflammation
involves the recruitment of neutrophils into the urinary
tracts and chemokines-chemokine receptor interactions. An
inhibition of mucosal signaling creates a state of asymp-
tomatic bacterial carriage (asymptomatic bacteriuria). Intri-
cate molecular interactions govern pathogen recognition on
mucosal surfaces as well as bacterial virulence. The innate
host defense mechanisms determine the severity of infection
[7].
For unknown reasons, UTIs are clustered in certain
individuals. UTIs are more prevalent in female relatives
of women with recurrent UTIs, which suggests a familial
genetic predisposition to the disease [8–10]. Animal models
have shown the multigenic nature of recurrent UTIs. Mouse
models of induced, unobstructed UTI have been important
in showing the influence of genetic factors on host suscep-
tibility and resistance to bladder and kidney infections [11,
12]. Other studies on both experimental mice and humans
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have disclosed that a predisposition to UTIrecurrences could
be inherited, suggesting that the increased susceptibility to
UTI is a complex heritable trait influenced by several genes
[13]. Putative candidate genes for the disease include genes
that are involved in the antimicrobial defense of surface
epithelia.
The objectives of this systematic review were to present
the genetic knowledge on the susceptibility to UTI recur-
rences in humans.
2. Methods
Using electronic databases, we looked for suitable com-
parative studies on children and adults that investigated
the genetic susceptibility to recurrent UTIs. Participants
were individuals of either gender with known or unknown
familial history of UTIs. UTIs occurred at both high
(pyelonephritis) or low (cystitis) urinary tract levels. We
excluded studies on animals. Clinical investigations for
UTIs included microbiological urinalysis and instrumental
investigations (ultrasound, voiding cystoureterogram and
DMSA scintigraphy). We excluded studies enrolling patients
with urinary tract obstruction. The included studies were
aimed at obtaining allele and genotype frequencies of gene
polymorphisms/mutations and gene expression of specific
loci recognized/suspected to be involved in UTIs recurrences
in both experimental patients and controls.
We searched the MEDLINE, SCOPUS and EMBASE sites
from 1985 through July 2009. We did not research literature
prior to 1985 because genes relating to UTIs recurrences
only began to be investigated in animals from 1985 [14, 15].
The first study that suspected a genetic predisposition to
UTI recurrences in both mice and humans was published
in 2000 [16]. The MeSH terms and text words (and their
combinations and truncated synonyms) were adapted as
appropriate to search each database by combining the
terms “urinary tract infection AND (genetic predisposition
OR genetic susceptibility OR genetic variation OR genetic
mutation OR genetic polymorphism) AND human.” We
also did a manual search of all the bibliographies from the
selected studies and from relevant review articles.
In some of the selected studies, we retrieved the genotype
frequency distribution for each gene polymorphism
investigated in patients with recurrent UTIs and controls.
We retrieved the odds ratio (OR) and the confidence
interval (95% CI) and/or the results of the statistical
analyses (P values) that compared the frequency of gene
polymorphisms between cases and controls. Moreover, we
retrieved information on mRNA levels and the protein
expression of candidate genes.
To our knowledge, no genome-wide association study
has been done on a large sample of individuals to discover
novel genetic caused susceptibility factors for UTIs. To date,
association with UTI has been studied from a candidate gene
approach only. The association between genetic variability
and clinical susceptibility to disease often lacks definitive
evidence due to methodological issues, high heterogeneity
and deaths which preclude meta-analytical association stud-
ies [25]. It is also worth noting that the significant genetic
associations reported could also include false positive results
[26]. Thus, we investigated the methodological quality of
each enrolled study. In particular, we looked to see if both
genetic and protein expressions were investigated in the same
study, if the ethnicity of the target population was reported,
if the Hardy-Weinberg equilibrium was ascertained in both
the case and control groups, if the authors declared any
UTIs recurrence and the presence or not of a urinary tract
malformation in their patients.
3. Results
Our initial search into the literature identified a large number
of papers from PUBMED (236 found), SCOPUS (680) and
EMBASE (80). After a hand screening for titles and abstracts,
21 studies were considered to be relevant to this review. A
closer look at these 21 papers excluded 11 papers because
they investigated the genetic susceptibility to renal damage
after aUTI [27–37]. Finally, ten studies were identified from
the literature as being eligible for this review [16–25]. Among
them, two studies referred to the same protocol and patients
[13, 16]. Seven studies investigated the frequency of target
gene polymorphisms in patients with recurrent UTIs [17, 18,
20–24], one of which lacked a control group [20]. Moreover,
five studies investigated the expression of mRNA or the
proteins of candidate genes associated with UTI recurrence
[16, 18–20, 23]. In summary, the nine studies we settled
on included only an assessment of gene polymorphisms
[17, 21, 22, 24], onlymRNA or protein expression assessment
[13, 16, 19] or both [18, 20, 23].
3.1. IL-8 Receptor CXCR1 and CXCR2 Genes. Frende´us et
al. investigated the neutrophil CXCR1 and CXCR2 surface
expressions in mice and humans. Twelve children with
recurrent UTIs showed decreased expression of CXCR1
protein and mRNA levels in neutrophils of children prone
to pyelonephritis [16]. CXCR2 expression was comparable
between patients and controls [13]. Smithson et al. inves-
tigated the surface expression of CXCR1 and CXCR2 as
well as the presence of CXCR1 gene polymorphisms in 20
premenopausal women with recurrent UTIs and normal
urinary tracts and 30 females with no history of UTIs.
CXCR1 expression was similar to that of healthy controls,
whereas CXCR2 expression was lower than in controls.
Sequence analysis of promoter and coding sequence of the
CXCR1 gene showed the presence of three polymorphisms
in the exon 2: one patient with R335C and two patients with
S276T [20]. The study by Lundstedt et al. investigated the
full-length CXCR1 gene sequence in 12 pediatric patients,
12 pediatric controls and 35 adults with childhood APN.
The frequency of relevant CXCR1 gene polymorphisms
was further assessed in 12 children, one adult, 14 control
children, and 200 healthy adult blood donors. The novel
217C>G polymorphism of the CXCR1 gene was located
in a putative binding site for the run-related transcript
factor 1 (RUNX1), which is required for expression from
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a number of cell specific enhancers and promoters. The
allele 217G was observed to be associated with a reduction
in RUNX1 binding. Moreover, aberrantly reduced CXCR1
mRNA processing from patients and mothers carrying the
A allele of the 3665G>A polymorphism suggested that this
variant might create a more eﬃcient cleavage site, reducing
the amount of large CXCR1 mRNA. Moreover, the CXCR1
expression by flow cytometry in 60 patients (24 children and
36 adults) with a history of childhood UTIs and controls
(26 children and 200 adults) showed low CXCR1 surface
neutrophil expression in patients prone to APN [18]. In
another paper, the same authors investigated the CXCR1
surface expression in 10 children with a history of APN and
recurrent UTI, as well as their families, and 15 controls.
CXCR1 expression was lower in the patients and their
families compared to controls [19].
3.2. Heat Shock Protein 72 (HSPA1B) Gene. Karoly et al.
investigated the frequency of the 1267A>G polymorphism of
the heat shock protein 72 gene (HSPA1B) and the frequency
of the TLR4 896A>G polymorphism in 103 children with
recurrent UTIs compared with 235 randomly selected con-
trols. Clinical investigations identified vesicoureteral reflux
(VUR) in 50 patients and renal scarring in 40 patients,
more commonly in those suﬀering from high-grade VUR.
The 1267G allele occurred more frequently in patients with
recurrent UTIs [17].
3.3. Toll-like Receptor (TLR) Pathway Genes. The 896/AG
genotype and the 896G allele of the TLR4 gene showed a
higher prevalence among UTI patients than among controls.
Moreover, the 896/AG genotype and 896G allele tended
to occur more frequently in patients with recurrent UTIs
without VUR [17].
Ragnarsdo´ttir et al. investigated the TLR4 protein expres-
sion in 17 children with asymptomatic bacteriuria (ABU)
and 24 controls. They found reduced expression of the
TLR4 protein. The authors recruited 41 pediatric and 29
adult patients and age-matched controls, to measure single
immunoglobulin domain-containing IL- 1 receptor-related
molecule (SIGIRR) and TLR4 adaptor protein TRIF expres-
sions (TIR domain containing adaptor inducing interferon-
β), TRAM (TRIF-related adaptor molecule) and MyD88
(Myeloid diﬀerentiation primary response gene 88). They
found high levels of the TLR4 adaptor protein TRIF and
reduced levels of the TLR4-inhibitor SIGIRR in the patients
with ABU. They proceeded with DNA sequencing of TRL4
DNA in 28 children with ABU and 14 controls but they
identified only one known missense mutation in one control
subject. The TRIF gene was sequenced in 12 children and
11 controls. The frequency of TRIF polymorphisms was
comparable between the patients with ABU and the control
subjects [23].
Tabel et al. investigated the 2258G>A polymorphism
(also described in the paper as G2251A or
rs5743708 referring to Arg753Gln: http://www.snpedia.com/
index.php/Rs5743708) of the TLR2 gene in 124 Turkish
children with a first time or recurrent UTI. This study
demonstrated a significantly higher frequency of the 2258A
allele in the TLR2 gene in patients with recurrent UTIs than
in 116 controls. The authors did not find any correlation
between a TLR2 gene polymorphism and the localization of
UTIs [22].
In a case-controlled designed study, Hawn et al. inves-
tigated the TLR pathway genes in 431 adult women with
recurrent UTIs and 430 controls. Nine TLR pathway genes
including TLR-1,2,4,5,6 and the genes of the TLR4 adap-
tor molecules MYD88, TIR domain containing adapter
(TIRAP), TRIF, and TRAM, were sequenced at DNA level.
In particular, 45 patients for the TLR2 gene, 43 for the
TLR4 gene, 46 for the TLR5 gene, 86 for the TIRAP
gene and 87 for the TRIF gene were investigated. The
TLR5 1174C>T gene polymorphism was associated with
increased susceptibility to recurrent cystitis. No significant
diﬀerence in the frequency of the 2258A allele of the TLR2
gene was found between adult women with UTI, including
urinary tract malformations (UTM), and controls. The
TLR1 1805G>T and TLR4 896A>G polymorphisms were
associated with protection from APN and recurrent cystitis,
respectively [21].
3.4. VEGF and TGF-β1. Yim et al. investigated vascular
endothelial growth factor (VEGF) and TGF-β1 gene poly-
morphisms with susceptibility to UTI. In particular, the
authors investigated two polymorphisms of the VEGF gene
(460T>C and 405G>C) and three polymorphisms of the
TGF-β1 gene (-509C>T, -800G>A and 869T>C). The overall
number of patients was 79, of which 48 patients had renal
scars and 57 had VUR, and 89 were controls. An increased
VEGF 460/CC, TGF-β1-509/CC, TGF-β1-800/GG genotype
frequency and decreased VEGF 460/TC, TGF-β-509/TT,
TGF-β1-800/GA genotype frequency were found in patients
with UTI when compared with control groups, both includ-
ing patients with VUR. Excluding patients with VUR, chil-
dren with UTIs showed an increased frequency of TGF-β1
-509/CC genotype when compared to a control group [24].
3.5. Summary of the Results. Table 1 summarizes the
main characteristics of the studies. Fourteen genes
were investigated, in particular 10 genes for one or
more polymorphisms, and 7 genes for their mRNA
levels or protein expression. Only two studies including
CXCR1 and TRIF genes combined the assessment of both
polymorphisms and protein expression in patients with and
without VUR [18, 23]. The majority of the studies included
patients with VUR and the minority included diﬀerent non-
obstructive UTMs. Only two studies investigated CXCR1,
CXCR2 protein expression and TLR2 polymorphism in
patients without UTMs [20, 22]. Study populations included
children only [13, 16, 17, 22, 24], both adults and children of
either sex [18, 19, 23], or only adult women [21]. In a quote
of the studies, the authors had not specified the ethnic group
of the patients [13, 16, 19, 20, 23].
Table 2 describes the genetic investigation of patients
with UTI susceptibility. The frequency of HSPA1B 1267A>G,
CXCR1 217C>G and CXCR1 2608G>C gene allele was
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Table 1: Summary of the characteristics of the included studies investigating the polymorphisms and/or mRNA or protein expression
assessment in patients with recurrent urinary tract infections (CXCR: IL-8 receptor; HSPA1B: Heat shock protein 72; TGF: Transforming
growth factor; TIRAP: TIR domain-containing adapter protein; TLR: Toll-like receptor; UTI: urinary tract infection; UTM: urinary tract
malformation; VEGF: Vascular endothelial growth factor; VUR: vesicoureteral reflux).
Genes Polymorphisms Gene expression Patient categories Ethnicity (country)
Urological
malformations
included
References
HSPA1B 1267A>G − Children Hungarian VUR [17]
CXCR1
— + Children (Sweden)
VUR
[13, 16]
217C>G +
Caucasians [18]
2608G>C + Children and adults
— + (Sweden) [19]
— + Pre-menopausal women (Spain) — [20]
CXCR2
— + Pre-menopausal women (Spain) — [20]
— + Children (Sweden) VUR [13, 16]
TLR1 1805G>T − Adult women Caucasian UTM [21]
TLR2 2258G>A
− Children Turkish — [22]
− Adult women Caucasian UTM [21]
TLR4
896A>G −
Adult women Caucasian UTM [21]
1196C>T −
896A>G − Children Hungarian
VUR
[17]
— + Mainly children (Sweden) [23]
TRIF 9A>G + Mainly children (Sweden) VUR [23]
TRAM — + Mainly children (Sweden) VUR [23]
MyD88 — + Mainly children (Sweden) VUR [23]
SIGIRR — + Mainly children (Sweden) VUR [23]
TLR5 1174C>T − Adult women Caucasian UTM [21]
TIRAP
589C>T −
Adult women Caucasian UTM [21]
558C>T −
VEGF
460T>C −
Children Korean VUR [24]
405G>C −
TGF- β1
509C>T −
800G>A − Children Korean VUR [24]
869T>C −
higher in patients with recurrent UTI than in control groups.
In particular, the OR of anHSPA1B 1267A>Gpolymorphism
was 3 times higher in patients with recurrent UTIs. The
study included patients with VUR of varied severity. No
information is available on patients without VUR for both
HSPAIB and CXCR1 polymorphisms [17, 19]. The OR of the
TLR1 1805G>T gene polymorphism was lower in patients
with pyelonephritis and comparable to those with cystitis
than in controls. This population study included patients
with urinary tract malformations [21]. The OR of TLR2
2258A allele was 3.1 times higher in children with recurrent
UTIs, without VUR, than in controls [22]. Moreover, the
OR of TLR2 2258A allele was not more significant in adult
women with UTIs, including those with UTM, than in con-
trols [21]. The frequency and OR of the TLR4 896A>G gene
polymorphism were lower in patients with recurrent cystitis
than in controls. The present study included patients and
controls with urinary tract malformations [21]. Moreover,
the frequency of a TLR4 896A>G gene polymorphism was
slightly lower although statistically comparable to patients
without VUR and controls. On the contrary, the OR was
twice as high in patients, including those with VUR, than in
controls [17]. The OR of the TLR4 1196C>T polymorphism
was lower in patients with recurrent cystitis than in controls
and comparable to patients with APN and controls. The
TLR5 1174C>T polymorphism was higher in patients with
recurrent cystitis and comparable to patients with APN and
controls, including patients with UTMs [21]. The frequency
of the VEGF 460T>C polymorphism was higher in patients
with UTI, including those with VUR, than in controls.
Therefore, the frequency was comparable in patients without
VUR but not with controls. Furthermore, the frequency of
TGF-β1 -509C>T and -800G>A polymorphisms were lower
in patients with UTI, including those with VUR, than in
controls. The frequency was comparable between patients
with UTI, without VUR, but not with controls [24].
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Table 2: Comparison of the genotype frequencies for each polymorphism studied in patients with recurrent urinary tract infection and in
controls. (CXCR: IL-8 receptor; HSPA1B: Heat shock protein 72; NS: not significant; PS: pyelonephritis; TGF: Transforming growth factor;
TIRAP: TIR domain-containing adapter protein; TLR: Toll-like receptor; UTM: urinary tract malformations; VEGF: Vascular endothelial
growth factor).
Gene Polymorphisms Urological condition also included
(infection type)
Patients/controls
(N/N)
Risk allele OR (95% CI) P value References
HSPA1B 1267A>G VUR 103/235 1267G 3.37 (1.04 –10.93) .036 [17]
CXCR1
217C>G VUR, (Pyelonephritis) 60/226 217G — .0007 [18]
2608G>C VUR, (Pyelonephritis) 60/226 2608C — <.001
TLR1 1805G>T UTM, (Pyelonephritis) 281/286
1805G 0.53 (0.29–0.96) .035 [21]
UTM, (Recurrent cystitis) 303/286 — 0.73 (0.46–1.17) NS
TLR2 2258G>A
— 124/116 2258A 3.14 (1.53–6.44) .001 [22]
UTM, (Pyelonephritis) 329/316 — 0.93 (0.48–1.81) NS [21]
UTM, (Recurrent cystitis) 337/316 — 0.83 (0.42–1.63) NS
TLR4
896A>G
UTM, (Pyelonephritis) 318/313 — 1.10 (0.69–1.75) NS [21]
UTM, (Recurrent cystitis) 334/313 896A 0.54 (0.32–0.93) .025
VUR 103/235 896G 2.19 (1.05– 4.57) .034 [17]
— 53/235 — 0.33 (0.10–1.12) .067
1196C>T UTM, (Pyelonephritis) 320/316
— 1.10 (0.69–1.75) NS
[21]
UTM, (Recurrent cystitis) 338/316 1196C 0.59 (0.35–0.998) .049
TRIF 9T>9 VUR 12/11 — — NS [23]
TLR5 1174C>T UTM, (Pyelonephritis) 320/315
— 1.17 (0.17–2.09) NS [21]
UTM, (Recurrent cystitis) 337/315 1174T 1.81 (1.00–3.08) .030
TIRAP
539C>T UTM, (Pyelonephritis) 318/314
— 0.86 (0.61–1.23) NS
[21]
UTM, (Recurrent cystitis) 338/314 — 0.88 (0.62–1.24) NS
558C>T UTM, (Pyelonephritis) 317/313
— 1.06 (0.77, 1.46) NS
UTM, (Recurrent cystitis) 329/313 — 1.30 (0.95, 1.78) NS
VEGF
460T>C VUR 63/71
460C
—
<.05
[24]
— 18/71 — NS
405G>C VUR 71/82
—
—
NS
— 19/82 — NS
TGF-β1
-509C>T VUR 78/80
-509C
—
<.05
[24]
— 21/80 — NS
-800G>A VUR 79/89
-800G
—
<.05
— 22/89 — NS
869T>C VUR 77/85
—
—
NS
— 20/85 — NS
Table 3 summarizes the studies concerning protein
expression in patients with susceptibility to UTI. Patients
with recurring UTIs showed lower expression levels of
CXCR1 than control patients did. The study included
patients with VUR of various degrees [13, 16, 18, 19].
Smithson et al., investigating premenopausal women with
recurrent UTI but no VUR, showed that CXCR1 expres-
sion was comparable to controls. However, women had
low expression levels of CXCR2 [20]. Ragnarsdattir et al.
compared TLR4 and the TLR4 adaptor proteins TRIF and
SIGIRR genes in children with asymptomatic bacteriurias,
including those with VUR, with controls. The TLR4 and
SIGIRR genes had reduced gene expression, whereas the
TRIF gene had increased expression [23].
3.6. Risk of Bias in Included Studies. Table 4 summarizes the
potential risks of bias for each study. One study completed
an analysis of both genetic polymorphisms and expression
of the CXCR1 gene [18]. Another study performed the
expression of the TRIF gene, but the frequency of the TRIF
polymorphism was performed in only one quote of these
patients (71% patients versus 46% controls) [23]. One study
assessed the CXCR1 expression, but the frequency of the
CXCR1 gene polymorphism was not estimated in the control
individuals [20]. Ethnicity was reported in five out of nine
studies [17, 18, 21, 22, 24]. Hardy-Weinberg equilibrium was
assessed in 3 out of 5 studies [17, 21, 22]. In four studies,
this assessment was not applicable [16, 18, 20, 23]. One
study, investigating for TGF-β1 and VEGF polymorphisms,
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Table 3: Comparison of the gene expression of patients with recurrent urinary tract infection and controls. (CXCR: IL-8 receptors; MyD88:
myeloid diﬀerentiation primary response gene 88; SIGIRR: single immunoglobulin domain-containing IL-1 receptor–related molecule;
TLR: Toll-like receptor; TRAM: TIR domain–containing adaptor inducing IFN-β-related adaptor molecule; TRIF: TIR domain–containing
adaptor inducing INF-β).
Protein expression Patients/controls (N/N) Patient values (range or ± SD) Control value (range or ± SD) P References
CXCR1
12/12 0.33 ± 0.23 1.33 ± 0.64 <.05 [13, 16]
60/226 −1.44 [−6.52–(1.04)]∗ 0.28 [−0.73–(2.15)]∗ <.0001 [18]
10/15 70% (42%–96%) 100% (77%–165%) .0006 [19]
20/30 118.9 (102.7–158.9) AU 116.2 (103.7–139.5) AU NS [20]
CXCR2 20/30 14.9 (12.82–17.23) AU 18.9 (16.2–23.6) AU .002 [20]
TLR4
17/24
33.2 (4.3–74.3) 56.1 (19.2–87.6) .003
MyD88 100.5 (9.3–197.3) 84.3 (9.9–168.5) NS
TRIF 139 (34.5–315.1) 85.1 (12.4–171.5) .02 [23]
TRAM 107.9 (32–262.9) 101.7 (39.8–269.2) NS
SIGIRR 14.9 (8.2–63.3) 21.9 (12.5–35.5) .0005
Legend :∗ : compared to a standard; AU: arbitrary unit.
did not clarify whether the patient had recurrent UTIs
although its objective was to assess susceptibility to UTIs.
These patients were enrolled at their first UTI [24]. One
study concerning TLR4 gene expression investigated for
primary and secondary bacteriurias [23]. In only one study,
concerning the TLR2 gene polymorphism, patients had no
urological malformations [22]. Two studies concerning the
HSPA1B, TLR4, VEGF, and TGF-β1 gene polymorphisms
performed the statistical analysis in a subgroup of patients
without VUR [17, 24].
4. Discussion
The first protection against a UTI involves physical bar-
riers (unidirectional urinary flow), epithelial cells and
the production of proteins that hinder bacteria adhesion
[38]. The structural variability of host cell glycoconju-
gates characterizes pathogen recognition at mucosal sites.
Subsequently, the oncoming inflammation activates the
uroepitelial cells, which produce mediators of inflammation,
until the pathogens are destroyed and eliminated. The func-
tional chemokines and chemokine receptors are crucial for
neutrophil recruitment and for neutrophil dependent bacte-
rial clearance. Moreover, the neutrophil-mediated defense is
essential for resistance to UTIs.
The inter-individual variability in cellular response may
be responsible for variable clinical outcomes and may
explain why certain individuals are susceptible to recur-
rent infections [38]. Susceptibility to UTIs is caused by
ineﬃcient bacterial clearance due to an impairment of
the innate host defense, such as low chemokine recep-
tor expression [16]. The neutrophils’ functional state is
influenced by the chemokine receptor expression of the
urinary tract. Thus, the neutrophil and local environment of
cytokine/chemokine/cell adhesion molecules, which govern
the intensity and persistence of the host response, have been
actively investigated [39].
Six out of 14 genes investigated in humans (HSPA1B,
CXCR1 and 2, TLR1,2,4,5, SIGIRR, TRIF, TRAM, MyD88
TIRAP, VEGF, and TGF-1β) may be associated with sus-
ceptibility to UTI recurrence in humans. In particular, the
HSPA1B, CXCR1 & 2, TLR2, TLR4 and TGF-β1 genes seem
to be associated at various levels with an alteration of the
host response to the UTI. The HSPA1B gene encodes a
70 kDa heat shock protein (HSP) that is a member of the
HSP70 family [17]. Patients with recurrent UTIs showed
a high prevalence of the HSPA1B 1267G allele [17]. The
CXCR1 gene encodes a human chemokine receptor gene
for IL-8 chemokine [18]. Mutational inactivation of the
CXCR1 causes both acute disease and chronic tissue damage
in mice [40]. Cell surface CXCR1 expression and CXCR1-
specific mRNA levels were low in the neutrophils of both
mice and children with recurrent UTIs [16]. Pyelonephritis
prone children showed low expression levels of CXCR1
[23]. Patients susceptible to UTIs after the age of 15 years
showed CXCR1 gene expression comparable to controls
[20]. However, humans with recurrent UTI showed a high
frequency of polymorphic allele (217G and 2608C) as well as
reduced gene expression [18]. Moreover, CXCR2 expression
in children aged 2–12 years at first manifestation of a UTI was
comparable to controls [13]; whereas premenopausal women
with recurrent UTI had lower CXCR2 expression than age-
matched controls [20]. These data seem to suggest that the
CXCR1 and CXCR2 genes could be associated with early or
late manifestation of susceptibility, respectively.
TLRs are a family of receptors that recognize pathogen-
associated molecules, and whose activation leads to the
transcription of appropriate host-defense genes and to the
recruitment of leucocytes [21]. Tabel et al. showed that
TLR2 2258A allele in children has been implicated in
susceptibility to gram-positive pathogens [22], but not in
adult women with UTI including those with UTMs [21].
However, genetic alteration of TLR4 signaling could modify
the host unresponsiveness to a UTI towards asymptomatic
bacteriuria (ABU) rather than symptomatic pyelonephritis
[41]. Children with asymptomatic bacteriuria expressed less
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Table 4: Methodological quality of each included study. The studies are listed according to their presentation along this review. (CXCR:
IL-8 receptor; MyD88: myeloid diﬀerentiation primary response gene 88; NA: not applicable; SIGIRR: single immunoglobulin domain-
containing IL-1 receptor-related molecule; TLR: Toll-like receptor; TRAM: TIR domain–containing adaptor inducing IFN-β–related adaptor
molecule; TRIF: TIR domain-containing adaptor inducing INF-β).
Authors Gene polymorphism(s)
Protein(s)
expression
Ethnicity
Hardy-
Weinberg
equilibrium
UTI
recurrence
Exclusion of
urinary tract
malformations
Lundstedt et al. [18] CXCR1 CXCR1 Caucasians − + −
Smithson et al. [20] CXCR1 [Unavailable controls]
CXCR1,
CXCR2
— NA + +
Lundstedt et al. [19] — CXCR1 — NA + −
Frende´us et al. [13, 16] — CXCR1 — NA + −
Hawn et al. [21] TLR1, TLR2,TLR4, TLR5,
TIRAP
— Caucasian + + −
Tabel et al. [22] TLR2 — Turkish + + −
Karoly et al. [17] TLR4, HSPA1B — Hungarian + + −
Ragnardosttir et al. [23] TRIF (assessed in a proportion
of patients)
TLR4, MyD88,
TRIF, TRAM
— NA
[asymptomatic
bacteriurias]
−
Yim et al. [24] VEGF, TGF-β1 — Korean − − −
TLR4 than age-matched controls [23]. However, the TLR4
gene showed comparable frequency of allele and genotype
[17, 21]. Thus, the authors extended the investigation to
TLR4 regulatory genes. In particular, the TRIF gene showed
increased expression and SIGIRR at reduced expression levels
[23]. Moreover, TGF-β1 -509T allele showed a protective role
in predisposition to recurrent UTIs because they were less
frequent in children with recurrent UTIs. TGF-β1 appears
to be a key cytokine involved in the regulation of cell
proliferation, diﬀerentiation, extracellular matrix formation
and immune response [24].
The available studies are heterogeneous for population
study and thus diﬃcult to compare with each other;
they studied diﬀerent ethnic groups, included patients
with urinary tract malformations of various types and
degree. They are limited in number which makes a meta-
analytical study impossible. However, the assessment of
protein expression was not performed for most of the
genes studied. Therefore, CXCR1 is the most important
gene that seems to be involved in susceptibility to recurrent
UTI. A reduced CXCR1 expression was observed in both
children and adults with recurrent UTI. It is likely that
these studies on the CXCR1 gene may be biased because
of inclusion of patients with VUR [16, 18]. Other genes
could be associated with UTI susceptibility: polymorphisms
of HSPA1B giving susceptibility [17] and TGF-1 β giving
protection [24], although these studies could be biased by
inclusion of patients with VUR. Limited information is
available on CXCR2, TLR2 and TLR4 pathways to arrive at
any conclusion on UTI susceptibility in humans. However,
TLR4 expression was reduced in children with recurrent
UTIs [23], whereas its 1196C>T polymorphism was shown
to be protective in adult women with recurrent cystitis [21].
These studies included patients with UTMs. The frequency
of HSPA1B (1267A>G), CXCR1 (217C>G, 2608G>C), TLR4
(1196C>T), TLR5 (1174C>T), VEGF (460T>C) and TGF-
β1 (-509C>T and -800G>A) polymorphisms were diﬀerent
between patients with recurrent UTI and controls, but the
study population included subjects with UTMs. In this
context, TGF-β1 protected from UTI recurrences in patients
with VUR. Finally, only three studies, investigating TLR2,
TLR4, VEGF, and TGF β1 polymorphisms, were conducted
on patients without VUR [17, 21, 24]; all but one (TLR2
2258G>A in children) showed no significant associations.
In particular, the frequency of TLR2 2258A allele was high
in children susceptible to UTIs [22]. These data have not
been recently confirmed in adult women with UTI, including
individuals with UTM [21]. The inclusion of patients of
diﬀerent ages and the presence of UTM make it impossible
to make a comparison between the two studies and oﬀer
conclusive remarks.
In conclusion, the pathophysiological background of
susceptibility to recurrent UTIs remains to be completely
clarified, taking into account that multiple factors, such as
gene-gene and gene-environmental interactions could be
involved. The kidney may act as a host where clusters of
bacteria persist as quiescent reservoirs surviving the immune
response and resisting antibiotic attacks. Moreover, recent
findings suggest that the genome of bacterial strains are
associated with either asymptomatic, commensal-like strains
that cause asymptomatic bacteriurias or with symptomatic
infections [42], suggesting that the simple colonization or
an infection can also be related to an interaction between
the bacterial gene-patient gene relationship. Recent advances
have suggested that a deregulation of candidate genes in
humans could possibly predispose patients to recurrent UTI.
The recognition of a genetic component in UTI recurrences
will make it possible to diagnose at-risk adults and to predict
genetic recurrences in their oﬀspring. Marked diﬀerences in
APN-associated morbidity between relatives of APN-prone
8 Journal of Biomedicine and Biotechnology
patients and the relatives of control subjects suggested that
inheritance could be autosomal involving one or more genes
[18]. For example, the combinations of polymorphisms of
CXCR1 and TGF-β1 in the same individual could have
additional eﬀects on susceptibility. The treatment options
with prophylactic antibiotics to prevent recurrent UTIs in
children remain of doubtful usefulness [43]. The identifica-
tion of susceptible patients could enable novel strategies in
the management of recurrent UTIs. Antagonists and agonists
of candidate gene products could manipulate host defense
mechanisms, oﬀering new therapeutic options to physicians
treating UTI [44].
Abbreviations
APN: Acute pyelonephritis
UTI: Urinary tract infection
UTM: Urinary tract malformation.
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